SIGN UP TO VIEW THE FULL ARTICLE

Receive a 90-day free trial of Celltelligence and get instant access to our full offering.

EMAIL BLASTS

Curated cell therapy industry news in your inbox multiple times each week

SEARCHABLE LIBRARY

A full archive of cell therapy news, insights, and context

THE MAP

A 24/7 information center that lets you make unique connections

The price for access is $0.00.

Do you have a discount code? Click here to enter your discount code.

Account Information

Username

Password

Confirm Password

Work E-mail Address

Confirm E-mail Address

Occupation

Other

Full Name LEAVE THIS BLANK

Payment Information We accept all major credit cards

Card Number

Expiration Date

CVC

Discount Code

I want to receive updates from celltelligence.com.

By selecting this, I agree to receive emails from celltelligence.com.

Processing...

Already have an account? Log in here

RETURN TO HOME

Autologous, CAR-T

December 01, 2021

2seventy’s SC-DARIC33 IND Cleared by the FDA for R/R Pediatric AML; 2seventy Q3 2021 Earnings Summary

Here is a brief preview of this blast: On Wednesday, December 1, 2seventy bio released their Q3 2021 financial results and operational updates (press release) highlighting their launch as an independent company. Moreover, management announced that the FDA has accepted an IND for SC-DARIC33’s (CD33 CAR-T) Ph1 PLAT-08 trial in r/r pediatric AML. Below, Celltelligence provides insights on 2seventy’s launch, while commenting on potential competitors for 2seventy’s SC-DARIC33 and bbT369 (CD20 x CD79a CAR-T) programs.

About The Author

The Celltelligence Team

Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.